"It is essential to demonstrate the ability to manufacture and deploy these medicines," said Chief Executive Patrick Amstutz.
(Reporting by John Miller; editing by Thomas Seythal)
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.255 CHF | -1.36% | -3.70% | -5.38% |
Mar. 15 | Transcript : Molecular Partners AG, 2023 Earnings Call, Mar 15, 2024 | |
Mar. 15 | Molecular Partners Swings to Loss in FY23; Revenue Down | MT |
Switzerland's Molecular Partners, which is hoping to produce an antiviral drug against COVID-19, said on Monday that it had completed initial manufacturing runs for its candidate MP0420 that it aims to test in humans starting in November.
"It is essential to demonstrate the ability to manufacture and deploy these medicines," said Chief Executive Patrick Amstutz.
(Reporting by John Miller; editing by Thomas Seythal)
1st Jan change | Capi. | |
---|---|---|
-5.38% | 119M | |
-0.23% | 103B | |
+3.41% | 96.73B | |
+1.22% | 21.31B | |
-15.62% | 21.21B | |
-6.26% | 18.79B | |
-41.41% | 16.37B | |
-22.29% | 13.68B | |
+7.23% | 13.44B | |
+24.15% | 10.98B |